Veeva Systems (VEEV) underscored its expanding role in AI-driven workflow automation at Citi’s 2026 Global Technology, Media, and Telecommunications Conference, emphasizing its deepening integration of artificial intelligence across its product suite. The company reported robust second-quarter growth, with commercial subscription revenue expanding by approximately 13% year-over-year, surpassing prior expectations of high single-digit increases. Services revenue also reached its highest growth in two years, while research and development (R&D) revenue, though historically growing at over 20% annually, is now stabilizing in the mid-teens range as mature products mature. Overall, Veeva’s product portfolio has expanded from 15 offerings in 2017 to over 50 across 10 suites, reflecting its expansion into AI-driven tools like Vault AI and Falcon. The company’s focus remains heavily on life sciences, accounting for nearly 98% of its total revenue, spanning commercial, regulatory, and quality management applications.
At the conference, Veeva CEO Peter Gassner and CFO Bryan Van Wagener highlighted how AI is reshaping operational efficiency in the sector. Van Wagener noted that agentic workflows—such as those in call reporting and regulatory inquiries—can reduce manual labor by up to 70%, cutting review timelines from months to under a week. For instance, agentic call reports can save sales representatives 30 to 45 minutes per call, while regulatory inquiries are now resolved in under a week, compared to months previously.
Veeva’s AI strategy also extends to its Vault CRM platform, which now serves over 180 customers. In a key migration trend, 12 of the top 20 customers have switched from Salesforce to Veeva, with 20 of the top 20 already using Veeva’s electronic Trial Master File (eTMF) solution. The company’s acquisition of Crossix in 2020—now integrated under its Compass data business—has further enhanced its precision targeting capabilities in healthcare, maintaining HIPAA compliance and anonymization.
The company’s stock closed at $260.21 on September 10, 2026, down 1.34% from the previous day, with a trailing price-to-earnings ratio of 43. Analysts have revised 25 earnings forecasts upward, reflecting optimism about Veeva’s growth trajectory. Van Wagener emphasized that AI will drive new revenue streams through transaction-based pricing models, such as Falcon, which will charge based on documents reviewed or inquiries resolved, rather than subscription fees. He also stressed that vertical software’s reliability—driven by deep industry expertise—positions Veeva to capture value in AI-driven efficiencies.
Looking ahead, Veeva targets 2030 as a key milestone for its AI initiatives, though no specific financial targets were disclosed. The company’s focus remains on expanding its AI capabilities while maintaining its dominance in life sciences software, where it competes with Salesforce and other horizontal platforms. The broader trend of AI adoption in healthcare and pharma is expected to sustain demand for Veeva’s solutions, particularly as companies seek to streamline regulatory, clinical, and commercial workflows.
